Daily Sepsis Research Analysis
Three impactful studies span neonatal sepsis management, mechanistic therapy for sepsis-induced lung injury, and benchmarking outcomes in pediatric in-hospital resuscitation. A neonatal RCT finds norepinephrine and dopamine have similar short-term efficacy but differing safety profiles; a preclinical study shows ADSC-derived exosomes mitigate lung injury via IRF7/NLRP3; and a validated model enables risk-standardized pediatric CPR survival benchmarking.
Summary
Three impactful studies span neonatal sepsis management, mechanistic therapy for sepsis-induced lung injury, and benchmarking outcomes in pediatric in-hospital resuscitation. A neonatal RCT finds norepinephrine and dopamine have similar short-term efficacy but differing safety profiles; a preclinical study shows ADSC-derived exosomes mitigate lung injury via IRF7/NLRP3; and a validated model enables risk-standardized pediatric CPR survival benchmarking.
Research Themes
- Vasoactive strategy in neonatal septic shock
- Exosome-based immunomodulation for sepsis-induced lung injury
- Risk-standardized benchmarking of pediatric in-hospital CPR outcomes
Selected Articles
1. Norepinephrine versus Dopamine for Septic Shock in Neonates: A Randomized Controlled Trial.
In a randomized trial of 80 neonates with fluid-refractory septic shock, norepinephrine and dopamine achieved comparable shock reversal at 30 minutes and similar secondary outcomes. However, dopamine was associated with more tachycardia, lower cerebral tissue oxygen saturation, and lower pH at 24 hours.
Impact: This trial provides rare randomized evidence in neonatal septic shock, informing first-line vasoactive choice with safety-relevant physiologic differences.
Clinical Implications: Given similar efficacy but less tachycardia and better cerebral oxygenation with norepinephrine, clinicians may prefer norepinephrine as first-line support in neonatal septic shock while awaiting larger confirmatory trials.
Key Findings
- Shock reversal at 30 minutes: 32% with norepinephrine vs 46% with dopamine (RR 0.69, 95% CI 0.39–1.20; P=0.19).
- Dopamine group had higher tachycardia, lower cerebral tissue oxygen saturation, and lower pH at 24 hours.
- Time to shock reversal, need for additional vasoactives/steroids, lactate levels, mortality, and other morbidities were comparable.
Methodological Strengths
- Prospectively registered randomized controlled design with predefined outcomes.
- Comparable baseline characteristics and clinically relevant physiologic endpoints.
Limitations
- Modest sample size may be underpowered for mortality and rare adverse events.
- Likely unblinded vasoactive administration and short primary follow-up (24 hours).
Future Directions: Larger multicenter RCTs powered for mortality and neurodevelopmental outcomes, and comparative studies of first- and second-line vasoactive strategies in neonates.
OBJECTIVE: To assess the effect of norepinephrine (NE) vs dopamine (DA) as first-line vasoactive agent in neonates with fluid-refractory septic shock. STUDY DESIGN: In this randomized controlled trial, 80 neonates with fluid-refractory septic shock were allocated to receive either NE (n = 41) or DA (n = 39) as the first-line vasoactive drug. NE and DA were initiated at a dose of 0.2 and 10 μg/kg/min and escalated to a maximum dose of 0.3 and 15 μg/kg/min, respectively. The primary outcome was the proportion of neonates with shock reversal at 30 minutes of initiation of vasoactive support. Other outcomes included time to shock reversal, requirement of additional vasoactive drugs and steroids, changes in cerebral tissue oxygen saturation, and acid-base parameters and lactate levels at 6-8 and 24 hours. Incidence of mortality, hyperglycemia, tachycardia, and other morbidities were recorded. RESULTS: Baseline characteristics were comparable between the 2 groups. The proportion of neonates with shock reversal at 30 minutes was 32% (13/41) and 46% (18/39) in NE and DA groups, respectively (relative risk 0.69, 95% CI 0.39-1.20, P = .19). Time to reversal of shock, need for additional vasoactive drugs and steroids, lactate levels, hyperglycemia, mortality, and other morbidities were comparable. However, neonates in the DA group had a higher incidence of tachycardia, lower cerebral tissue oxygen saturation, and lower pH at 24 hours of recruitment. CONCLUSION: In neonates with septic shock, NE and DA had comparable efficacy as a first-line vasoactive agent. CLINICAL TRIAL REGISTRATION: Clinical trial registry of India, registration no: CTRI/2023/02/049357, registered prospectively on: 01/02/2023, https://trialsearch.who.int/.
2. Therapeutic potential of ADSC-derived exosomes in acute lung injury by regulating macrophage polarization through IRF7/NLRP3 signaling.
In LPS-induced ALI, ADSC-derived exosomes reduced lung inflammation and injury, shifted macrophage polarization from M1 to M2, and suppressed NLRP3-mediated pyroptosis. RNA-seq identified IRF7 as an upstream node; IRF7 overexpression or exosome secretion blockade abrogated the protective effects.
Impact: This mechanistic work links exosomal therapy to IRF7/NLRP3 signaling to control macrophage fate, advancing a targeted approach for sepsis-induced lung injury.
Clinical Implications: While preclinical, the data support exploring ADSC-exosomes as an immunomodulatory therapy for sepsis-related lung injury and inform biomarker selection (IRF7/NLRP3) for early-phase trials.
Key Findings
- ADSC-Exos attenuated lung inflammation and injury in LPS-induced ALI mice (histology, ELISA, immunofluorescence).
- In MH-S cells, ADSC-Exos decreased M1 markers (iNOS, CD86) and increased M2 markers (CD206, Arg-1).
- IRF7 was identified as an upstream regulator; ADSC-Exos inhibited NLRP3 inflammasome and pyroptosis, and IRF7 overexpression or GW4869 blocked these benefits.
Methodological Strengths
- Integrated in vivo and in vitro models with convergent readouts (histology, ELISA, flow cytometry, Western blot).
- Mechanistic validation via RNA-seq, IRF7 overexpression, and pharmacologic inhibition of exosome secretion.
Limitations
- Preclinical LPS model may not recapitulate polymicrobial sepsis and human ARDS complexity.
- Dosing, pharmacokinetics, and exosome cargo responsible for effects were not fully defined.
Future Directions: Validate in polymicrobial sepsis/ventilator-injury models and large animals; characterize exosome cargo; assess safety and dosing in early-phase clinical trials.
Alveolar macrophages (AMs) play a critical role in regulating pulmonary immunity and inflammation. Acute lung injury (ALI), frequently initiated by sepsis-induced systemic inflammation and cytokine storms, leads to heightened lung permeability and respiratory failure. Adipose-derived stem cell exosomes (ADSC-Exos) have shown promise as therapeutic agents due to their immunomodulatory properties. This study assesses the effectiveness of ADSC-Exos in mitigating ALI by modulating macrophage (mø) polarization and suppressing pyroptosis. In vivo, an LPS-induced ALI mouse model demonstrated that ADSC-Exos attenuated lung tissue inflammation and damage, as verified by histological staining, ELISA, and immunofluorescence. In vitro, LPS-stimulated MH-S cells treated with ADSC-Exos showed a decrease in M1 (iNOS, CD86) and an increase in M2 (CD206, Arg-1) markers, as evidenced by Western blotting (WB) and flow cytometry. Mechanistically, RNA sequencing pinpointed IRF7 as a key upstream regulator of pyroptosis. ADSC-Exos inhibited the NLRP3 inflammasome and pyroptosis, fostering a shift from pro-inflammatory M1 to anti-inflammatory M2 mø phenotypes. Overexpression of IRF7 negated these effects, undermining the protective role of ADSC-Exos. Notably, inhibition of exosome secretion with GW4869 nullified these immunomodulatory effects, underscoring the vital role of ADSC-Exos. This study underscores the therapeutic potential of ADSC-Exos in restoring alveolar mø homeostasis, modulating immune responses, and alleviating lung inflammatory injury in ALI. These findings suggest ADSC-Exos as a feasible strategy for treating sepsis-induced pulmonary complications.
3. Risk-standardizing hospital rates of survival for pediatric in-hospital CPR events.
Using 8,080 pediatric CPR cases from a national registry, the authors derived and validated a 13-predictor hierarchical model with strong discrimination (c≈0.77) and good calibration to compute hospital risk-standardized survival rates. Bradycardia with poor perfusion accounted for 56.4% of events.
Impact: Provides a validated, parsimonious risk-standardization tool enabling fair benchmarking of pediatric in-hospital CPR outcomes, including bradycardia with poor perfusion.
Clinical Implications: Hospitals can use risk-standardized survival to benchmark performance, identify gaps, and target quality improvement, potentially benefiting children with arrest from sepsis and other etiologies.
Key Findings
- Developed a hierarchical logistic regression model for pediatric CPR survival with 16 predictors (c=0.772) and a parsimonious 13-predictor version (c=0.769).
- Model demonstrated good calibration in a validation cohort and supports hospital-level risk-standardized survival rate (RSSR) estimation.
- Bradycardia with poor perfusion constituted 56.4% of pediatric in-hospital CPR events.
Methodological Strengths
- Large, contemporary multicenter registry with derivation and validation cohorts.
- Hierarchical modeling accounting for hospital-level variation and inclusion of bradycardia with poor perfusion.
Limitations
- Registry-based observational design with potential residual confounding and variable capture limitations.
- Generalizability outside the Get With the Guidelines-Resuscitation network remains to be established.
Future Directions: External validation across diverse health systems and integration into quality dashboards to guide targeted resuscitation improvement initiatives.
BACKGROUND: Bradycardia with poor perfusion is the most common reason for in-hospital cardiopulmonary resuscitation (CPR) in children. To date, validated methods to risk-standardize pediatric survival rates for CPR events in hospitals that includes bradycardia with poor perfusion do not exist. METHODS: Within Get With the Guidelines-Resuscitation, we identified 8080 children who underwent CPR between 2016 and 2023. Using hierarchical logistic regression, we derived and validated a model for survival to hospital discharge to calculate risk-standardized survival rates (RSSRs) for hospitals. RESULTS: Bradycardia with poor perfusion comprised 56.4% of pediatric CPR events. An initial full model in the derivation cohort identified 16 predictors of survival (c-statistic = 0.772), and a parsimonious model with 13 predictors maintained good discrimination (c-statistic = 0.769). The model calibrated well in the validation cohort (R CONCLUSION: We developed and validated a model to risk-standardize hospital rates of survival for children undergoing CPR, including those with bradycardia and poor perfusion. This model can facilitate efforts to benchmark hospitals in resuscitation outcomes for children.